4-Benzyl-2-(naphthalen-1-yl)-[1,2,4]thiadiazolidine-3,5-dione

Min.Order / FOB Price:Get Latest Price

100 Gram	FOB Price: USD 350.0000

100 Gram

FOB Price: USD 350.0000

Min.Order :100 Gram
Purity: 99% min
Payment Terms : L/C,T/T,Other

Keywords

Tideglusib CS-0613 865854-05-3

Quick Details

Appearance:white to beige powder
Application:/
PackAge:1KG/Bag 25KG/drum
ProductionCapacity:100|Kilogram|Month
Storage:Cool and dry place
Transportation:Air

Superiority:

Wuhan Senwayer century chemical Co..Ltd located in the predominant Wuhan City where is a traffic hinge of China, specialize in producing and developing pharmaceutical & its intermediates, Pesticide Intermediate, food additive, Plant extracts,and in distributing the products of our own company and affiliated enterprises.

We have set up R&D center, quality inspection center and manufacturing site in Wuhan, Jiangsu and other places.

Our company has professional staff who deal with chemical R&D and scientific management, and holds several sets of analyzing instruments with high efficiency and high sensitivity, such as HPLC, GC and Spectrophotometer. Meanwhile, we possess of complete Q.A. and Q.C. system, supply chemical products with good quality and custom-tailored products according to our clients' requirement.

We have professional sales team, focus on quality and service, and we have achieved excellent performance over the years. Our company is committed to the development of international market , our products are mainly exported to many countries and regions, such as Europe, America, South-east Asia, the Middle East and Africa etc. With our constant efforts and good service, We sincerely hope to establish long-term cooperation and common development with our customers.

Details:

Product name	Tideglusib
CAS No.	865854-05-3
MF	C19H14N2O2S
MW	334.39
Shelf Life	2 Years

Product description

Tideglusib is an orally available, small-molecule drug of the thiadiazolidinone class. It acts as an inhibitor of glycogen synthase kinase 3 (GSK3-β), a widely studied tau kinase. The rationale for its use is that inhibiting GSK3-β will counteract tau hyperphosphorylation, which is thought be a step in the cellular pathogenesis that leads to Alzheimer's disease and other neurodegenerative diseases marked by neurofibrillary tau pathology. Tideglusib was being developed for the treatment of Alzheimer's and the tauopathy progressive supranuclear palsy (PSP) as part of a drug-discovery program based on marine-derived GSK3-β inhibitors.

View All

Visit Store